Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGuIX® + WBRT in Multiple Brain Metastases
NCT03818386Phase 2Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Mar 2019
- Primary completion
- Sep 2024
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of AGuIX in brain metastases (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Best objective intracranial response rate - intent-to-treat at 3 months. Started Mar 2019; status: completed.
02
Drugs
AGuIX
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT03818386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03818386.